Smart radiation seeks out cancer cells in 8 tumor types

NCT ID NCT06710756

Recruiting now Disease control Sponsor: Perspective Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests a new drug that delivers a tiny dose of radiation directly to cancer cells that have a specific marker called FAP. The trial involves 112 adults with advanced cancers of the pancreas, stomach, esophagus, colon, ovary, head/neck, sarcoma, or mesothelioma. First, a small imaging dose is given to see if the drug reaches the tumors. Then, a treatment dose is given to try to shrink the cancer. The goal is to find a safe dose and see if it helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A radioactive drug (lead-212 attached to a targeting molecule) that seeks out and delivers radiation to cancer cells with a specific marker (FAP).
What this could lead to: If it works, this could offer a new treatment option for several hard-to-treat cancers that have not responded to standard therapies.
What could go wrong: This is an early-phase trial (phase I/IIa) with a small number of participants, so safety and effectiveness are not yet proven. The treatment involves radiation, which may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm head and neck cancer Head and Neck Neoplasms mesothelioma ovarian cancer pancreatic ductal adenocarcinoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER ESOPHAGEAL CANCER GASTRIC CANCER HEAD AND NECK CANCER MESOTHELIOMA OVARIAN CANCER PANCREATIC DUCTAL ADENOCARCINOMA SARCOMA

Contacts and locations

Show contact details

Locations

Biogenix
RECRUITING

Miami, Florida, 33165, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Mayo Clinic in Rochester, Minnesota
RECRUITING

Rochester, Minnesota, 55905, United States
Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States
Ohio State University
RECRUITING

Columbus, Ohio, 43221, United States
Saint Louis University
RECRUITING

St Louis, Missouri, 63110, United States
University of Kansas
RECRUITING

Kansas City, Kansas, 66205, United States
University of Kentucky
RECRUITING

Lexington, Kentucky, 40536, United States
University of Miami
RECRUITING

Miami, Florida, 33125, United States
University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53792, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.